首页
DAB2IP在膀胱移行细胞癌组织中的表达及与临床预后的相关性研究
DAB2IP Expression in Bladder Transitional Cell Carcinoma and Its Correlation with Clinical Outcome
-
摘要: 目的 探讨DAB2IP在膀胱移行细胞癌 （transitional cell carcinoma of bladder，TCCB）组织中的表达及与膀胱癌患者预后的相关性。方法 收集79例膀胱移行细胞癌组织和11例正常膀胱组织，用免疫组化方法检测DAB2IP的表达，分析染色结果与肿瘤病理分级、临床分期、淋巴结转移和患者性别、年龄及术后3年生存率之间的关系。结果 膀胱移行细胞癌中DAB2IP表达量低于正常膀胱上皮，而在高级别、浸润性或转移性癌组织中DAB2IP的阳性表达率及评分低于低级别、浅表性、非转移性癌组织，差异均有统计学意义 （P<0.05）；而且DAB2IP表达高的患者术后3年生存率高于低表达患者。结论 DAB2IP可能是TCCB发生、发展中一种重要的抑制分子，有望成为TCCB基因治疗的新靶点。Abstract: Objective To investigate the expression of DAB2IP in bladder transitional cell carcinoma (BTCC) and its correlation with clinical characteristics and prognosis of BTCC patients. Methods Immunohistochemical staining was applied to detect DAB2IP protein level in 79 cases of TCCB tissues and 11 cases of normal bladder tissues, and the relationships of the staining results with pathological grade, stage, lymph node metastasis, gender, age and the 3-year survival rate of the patients were analyzed. Results The expression of DAB2IP in BTCC tissues was significantly lower than that in normal bladder epithelium, and the expression score and rate of DAB2IP in the high-grade, invasive and metastatic BTCC were significantly lower than those in low-grade, superficial and non-metastatic BTCC (P<0.05).The 3-year survival rate of the patients with high DAB2IP expression was significantly higher than that of the patients with low DAB2IP expression. Conclusion DAB2IP may be one of the important inhibitory factors during the occurrence and progression of BTCC.
-
-
期刊类型引用(4)
1. 张婷婷, 谢秀英. R11介导的DAB2IP功能片段P10对宫颈癌细胞系Siha放疗增敏效应的研究. 中国生育健康杂志. 2017(06): 583-586+600 . 
百度学术
2. 谢宣刚, 尤建川, 李银河. 胃癌患者DAB2IP的表达及预后意义. 解放军医药杂志. 2016(12): 45-47+58 . 百度学术
3. 章婷婷, 陈莹, 王浩, 孔肇路. DAB2IP基因沉默引起膀胱癌细胞辐射耐受与化疗抵抗. 标记免疫分析与临床. 2015(06): 549-551+558 . 百度学术
4. 舒畅, 吴振启. 不同剂量吡格列酮对膀胱癌上皮细胞生长的影响. 检验医学与临床. 2015(19): 2878-2879 . 百度学术
其他类型引用(1)
计量
- 文章访问数: 2604
- HTML全文浏览量: 101
- PDF下载量: 149
- 被引次数: 5
下载:
